Showing results (101-110 of 132) with videos related to
Sort By:
Pageof 14
JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.Science Translational Medicine|December 20, 2013
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancerHiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.Journal for Immunotherapy of Cancer|June 10, 2022
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapyMichael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, et al.JAMA Surgery|December 23, 2020
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung AdenocarcinomaGregory D Jones, Whitney S Brandt, Ronglai Shen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Neoadjuvant Osimertinib for Resectable <i>EGFR</i>-Mutated Non-Small Cell Lung CancerJianxing He, Masahiro Tsuboi, Walter Weder, et al.Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.Pageof 14